Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Recommendation of “Hold” from Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has earned a consensus recommendation of “Hold” from the fourteen research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $41.3333.

Several research firms have issued reports on CNTA. Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. B. Riley Financial downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective on the stock. in a report on Monday, April 13th. Finally, Stephens downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. TD Waterhouse Canada Inc. acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $36,000. T. Rowe Price Investment Management Inc. increased its holdings in shares of Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $100,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $40.50 on Wednesday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The firm’s fifty day moving average price is $39.79 and its two-hundred day moving average price is $31.83. Centessa Pharmaceuticals has a 1 year low of $12.74 and a 1 year high of $40.56. The firm has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, research analysts anticipate that Centessa Pharmaceuticals will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.